Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
Status:
Recruiting
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This open label, randomized, controlled, investigator-initiated, multi-centre trial aims to
establish metabolic improvements in COVID-19 subjects by dietary supplementation with
cofactors N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine plus
standard therapy. The primary objective is to assess the clinical efficacy of the combination
of metabolic cofactors supplementation and hydroxychloroquine in COVID-19 patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
ScandiBio Therapeutics AB
Collaborators:
Alanya Alaaddin Keykubat University Alanya Training and Research Hospital Bagcilar Training and Research Hospital Bakirkoy Dr. Sadi Konuk Research and Training Hospital Canakkale 18 Mart University Health Research and Application Hospital Dr. Lutfi Kirdar Kartal Training and Research Hospital Istanbul Medipol University Hospital Istanbul Umraniye Training and Research Hospital Kanuni Sultan Suleyman Training and Research Hospital Monitor CRO